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ABSTRACT 
Tuberculosis remains the world’s deadliest infectious killer despite the availability of highly 
efficacious treatment for decades and one of the top 10 causes of death worldwide. As per WHO, 
global report 2019 Eight countries accounted for 66% of the new cases with India (27%) at top. 
Anti-TB drugs are one of the commonest group underlying idiosyncratic hepatotoxicity worldwide. 
Ayurveda is living science which is helpful to each individual to be a healthy by advocacy of lifestyle 
and treatment by universal principle. In present scenario the role of Ayurveda in the management 
of TB is very scanty and mostly limited to adjunct or supportive therapy which cannot be simply 
neglected. In this review an attempt is made to throw a light on history of tuberculosis, it’s related 
literature in Ayurveda classics, different Kalpas and drugs which may useful, and their anti-
tubercular potential and current trend of practice and research on tuberculosis. The main objective 
is to make familiar the researchers and readers to take further initiative in future to conduct more 
research on this contagious killer disease. 
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INTRODUCTION 
Tuberculosis (TB) is a communicable disease 
caused by bacteria (Mycobacterium tuberculosis) 
that most often affect the lungs but can also affect 
other sites (extra-pulmonary TB). Tuberculosis is 
curable and preventable1. TB is transmitted from 
person to person through coughing and breathing in 
airborne droplets that contain bacteria. As one of the 
most common infections in the world, TB remains a 
foremost problem in many countries and among 
vulnerable populations2. The theme of World TB Day 
2019 - ‘Its time’ – puts the accent on the urgency to 
act on the commitments made by global leaders, 
World Health Organization (WHO) has launched a 
joint initiative “Find. Treat. All. #End TB3” 
People infected with Mycobacterium 
tuberculosis bacteria have a 5–15% lifetime threat of 
falling ill with TB. Persons with compromised 
immune systems, such as known cases of HIV, 
malnutrition or diabetes, or people, who addicted for 
tobacco, have a higher risk of falling ill. When a 
person develops active TB disease, the symptoms 
(such as cough, fever, night sweats, or weight loss) 
may be mild for many months. This may lead to 
delays in seeking care, and results in transmission of 
the bacteria to others. People with active TB can 
infect 5–15 other people through close contact over 
the course of a year. Without proper treatment, 45% 
of HIV-negative people with TB on average and 
nearly all HIV-positive people with TB will die4. India 
contributes to one-fourth of the global burden of 
multidrug-resistant tuberculosis (MDR-TB) with 
inadequate diagnostic infrastructure for drug 
susceptibility testing (DST)5. 
According to an estimate of World Health 
Organization (WHO), an approximately 85–90% of 
the world's population consumes traditional 
medicines due to better tolerance and fewer adverse 
drug reactions. Indeed, both general practitioners 
and specialists use various types of traditional 
medicines to support Tuberculosis management. 
Ayurveda have some solutions to these problems. 
Different names used for TB6  
Tuberculosis, Phthisis, Tabes, Schachepheth, 
“The white plague“, Consumption, Captain of all these 
men of death, Scrofula. 
Today, we classified TB from where it is 
located (pulmonary, extrapulmonary) and the way to 
treat (drug- susceptible, drug- resistant, multidrug 
resistant, and extensively drug-resistant6.  
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History of Tuberculosis in Global and Indian 
Scenario 
It has been hypothesized that the genus 
Mycobacterium originated more than 150 million 
years ago. In the Middle Age, Scrofula, a disease 
affecting cervical lymph nodes, was described as a 
new clinical form of TB. The illness was known in 
England and France as “king’s evil”, and it was widely 
believed that persons affected could heal after a royal 
touch. In 1720, for the first time, the infectious origin 
of TB was conjectured by the English physician 
Benjamin Marten, while the first successful remedy 
against TB was the introduction of the sanatorium 
cure. The famous scientist Robert Koch was able to 
isolate the tubercle bacillus and presented this 
extraordinary result to the society of Physiology in 
Berlin on 24 March 1882. In the decades following 
this discovery, the Pirquet and Mantoux tuberculin 
skin tests, Albert Calmette and Camille Guérin BCG 
vaccine, Selman Waksman streptomycin and other 
anti-tuberculous drugs were developed7.  
TB has been part of the human experience for 
a long time, in humans can be traced back to 9,000 
years ago in Atlit Yam, a city now under the 
Mediterranean Sea, off the coast of Israel. 
Archeologists found TB in the remains of a mother 
and child buried together. The earliest written 
mentions of TB were in India (3,300 years ago) and 
China (2,300 years ago)6.  
TB in India is an ancient disease. In Indian 
literature there are passages from around 1500 BCE 
in which consumption is mentioned, and the disease 
is attributed to excessive fatigue, worries, hunger, 
pregnancy and chest wounds. Sanskrit manuscripts 
around 500 BCE which are the texts from which the 
Ayurveda system of general Indian medical practice 
is derivedthere is a group of diseases referred to as 
Shosha with a prominent feature of wasting, and 
there are other symptoms such as “cough and blood-
spitting”. It is also said that the Moon-god, the king of 
the Brahmanas was the first to become a victim of 
this disease, which is as a result also known as 
Rajayakshma, or king’s disease.  
In Madhukosha, one of the commentaries of 
Madhavnidana describes the disease referred to in a 
number of different texts as Yakshma, consumption 
or Rajyakshma (kingly consumption) and it also 
refers to how it has been identified by many as being 
what is in the twenty first century called 
Tuberculosis. However, the commentary also said 
that ancient disease Yakshma had a much wider 
range than TB and covers a number of conditions 
between physical exhaustion through to cachexia or 
physical wasting8. 
 
TB disease burden 
A total of 1.5 million people died from TB in 2018 
(including 251000 people with HIV). Worldwide, TB 
is one of the top 10 causes of death and the leading 
cause from a single infectious agent (above 
HIV/AIDS). In 2018, the 30 high TB burden countries 
accounted for 87% of new TB cases. Eight countries 
account for two thirds of the total, with India (27%), 
leading the count, followed by, China (9%), Indonesia 
(8%), the Philippines (6%), Pakistan (6%), Nigeria 
(4%), Bangladesh (4%) and South Africa (3%)9. 
Multidrug-resistant TB (MDR-TB) remains a 
public health crisis and a health security threat. WHO 
estimates that there were 484000 new cases with 
resistance to rifampicin – the most effective first-line 
drug, of which 78% had MDR-TB4. In 2018, India was 
able to achieve a Total Notification of 21.5 LakhTB 
cases10. It is estimated that about 40% of the Indian 
population is infected with TB bacteria, the vast 
majority of whom have latent TB rather than TB 
disease11. 
Role of Immunity in Tuberculosis and HIV: 
The risk of developing TB is estimated to be 
between 16-27 times greater in people living with 
HIV than among those without HIV infection. In 2015, 
there were an estimated 10.4 million cases of 
tuberculosis disease globally, including 1.2 million 
[11%] among popilation living with HIV. Almost 60% 
[57%] of tuberculosis cases among people living with 
HIV were not diagnosed or treated, resulting in 390 
000 tuberculosis-related deaths among people living 
with HIV in201512. 
An article lead to, M. tuberculosis and HIV act 
in synergy, accelerating the decline of immunological 
functions and leading to subsequent death if 
untreated. An author gave some evidences about 
mechanisms behind the breakdown of the immune 
defense of the co-infected individual to highlight 
immunological events that may accelerate the 
development of one of the two diseases in the 
presence of the coinfecting organism.  
Cell-mediated immunity play an important 
role for control of M. tuberculosis infection; activation 
of both CD4+ and CD8+ T cells is seen in active TB in 
humans as well as in mice after experimental 
infection. 
Programmed- Death 1 (PD-1) and T cell 
immunoglobulin and mucin domain 3 (Tim-3) are 
two examples of markers of T cell exhaustion in HIV-
1+ patients caused by constant antigenic stimulation. 
The publication reports that Tim-3 was up-regulated 
on antigen-specific CD8+ T cells in patients with 
active TB, indicating that similar inhibitory receptor/ 
ligand interactions play a role in modulating host 
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immunity to both HIV and M. tuberculosis infections 
in humans13. 
Antitubercular Drugs and Hepatotoxicity 
Omaima El Bouazzi et al. stated that 
Hepatotoxicity is the most common adverse reaction 
of anti-TB treatment that leads to interruption of 
therapy. The exact mechanism of Antitubercular drug 
induced hepatotoxicity (ATDH) is not well defined 
but is due to toxic metabolites. Studies reported in 
several countries are shown in the Orientals are 
reported to have the highest rates, especially Iran 
(27.7%) and Pakistan (19.7%). However other 
studies reported in developed countries showed low 
incidences (USA, Spain and Dutch). The incidence of 
ATDH is much higher in studies from developing 
countries compared with developed countries. 
Several factors can be at the origin of this difference 
as: Malnutrition, chronic co-infections, ethnic factors 
or genetic predisposition14. 
The liver has a central role in drug 
metabolism and detoxification; and is consequently 
vulnerable to injury. The pathogenesis and types of 
drug induced liver injury (DILI) are presented, 
ranging from hepatic adaptation to hepatocellular 
injury15.  
Chart 1: Showing Diagnostic protocol as per modern system of medicine16
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chart 2: Drug regimen ofRevised National Tuberculosis Control programme (RNTCP)16 
Treatment 
Groups 
Type of Patient Regimen 
Intensive Phase Continuation phase 
New 
(Cat I) 
New sputum smear positive 
New sputum smear negative 
New extra-pulmonary 
New others 
2H3R3Z3E3 4H3R3 
Previously 
Treated 
(Cat II) 
Smear positive relapse 
Smear positive failure 
Smear positive treatment after default 
Others 
2H3R3Z3E3S3 
1H3R3Z3E3 
5H3R3E3 
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Tuberculosisin Ayurveda perspectives17,18,19 
Ayurveda is a whole medical system that is 
based on various theories about health and illness 
and on ways to prevent, manage, or treat health 
problems. Tuberculosis is not a modern disease; in 
fact, it is mentioned in the Rigveda, which was 
written over 3500 years ago. Tuberculosis is 
compared to Rajyakshma mentioned in Ayurvedic 
treatises. Rajayakshma is primarily attributable to 
Dhatukshaya (tissue emaciation or loss), also termed 
as Shosha. In Charak Samhita Krodha, Yakshma, Jvara, 
Roga and Dukha are used as synonyms to each other.  
In Ayurveda four types of pathophysiological 
factors considered for Yakshma i.e., 
Ayathabalamarambham or Sahas ((physical exertion 
disproportionate to strength), Vegasandharanam 
(suppression of natural urges), Kshayam (wasting) & 
Vishamashanam (improper diet). According to the 
pathophysiological factor different types of sign and 
symptoms are observed in the patient. This process 
universally initiates the process of pathogenesis 
in Rajayakshma patients. In the Ayurveda Yaksma has 
been classified on the basis of cluster of symptoms 
observed in Yakshma patients like Trirupa Yakshma, 
Shadrupa Yaksma and Ekadashrupa Yakshma. As per 
Ayurvedic concepts Yaksma is considered as 
Tridoshja Vyadhi, there is inevitable metabolic 
dysfunction (Dhatwagninasana), in which Rasa 
(tissue fluid), Rakta (blood), Mamsa (muscle), Meda 
(adipose tissue), and Shukra (generative tissue) are 
lost. This leads to ultimate deterioration of immunity 
or Ojokshaya. As per the pathophysiological process 
involved in the body the Yaksma has been classified 
as Anuloma or Pratiloma Yakshma. 
An observational study suggests that 
unwholesome diet and irregular dieting, exertion, 
suppressing of the natural urges and stressful 
lifestyle play an important role in the manifestation 
of tuberculosis disease. Trirupa (3 symptoms) and 
Shad Rupa (6 symptoms) are found in earlier stage of 
the tuberculosis and Ekadasharupa (11 symptoms) in 
chronic condition of tuberculosis20.  
Chart 3: Showing sign and symptoms in patient of Rajyakshma as per Charak Samhita. 
Early stages clinical features of Rajyakshma 
(Tuberculosis) 
Clinical features of Chronic condition of 
Rajyakshma (Tuberculosis) 
Trirupa Yakshma Shadrupa Yakshma Ekadashrupa Yakshma 
1. Amsa –Parshvaabhitapa 
(Distress in shoulder and 
Chest) 
2. Kara-Pada samtap 
(Burning sensation in 
hands and feet) 
3. Jwara (Fever) 
1. Parshvashoola (Pain in 
sides) 
2. Kasa (cough) 
3. Jwara (Fever) 
4. Swarabheda (Hoarseness 
of voice) 
5. Atisaara (Diarrhoea) 
6. Aruchi (Anorexia) 
1. Parshvashoola (Chest pain) 
2. Kasa (Cough) 
3. Jvara (Fever) 
4. Swarabheda (Hoarseness of voice 
5. Atisaara (Diarrhoea)  
6. Aruchi (Anorexia) 
7. Amsashoola (Shoulder pain) 
8. Shirshoola (Headache) 
9. Raktachardi (Haemoptysis) 
10. Shthivan/ Kapha Sraava (Excretion of 
sputum) 
11. Shvasa (Dyspnoea) 
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Chart 4: Probable mode of Samprapti in Rajyakshma disease 
 
      
 
 
 
 
 
 
 
 
 
 
     
  
     
      
          
 
              
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vegadharana 
Nidana 
Sahasaja Kshayaja 
Shukra Kshaya  
Vata Dushti 
Vishamashana 
Tridosha Dushti 
Kapha- Pitta Dushti 
Rukshadi Ahara 
Strotovarodha 
Dhatvagni Mandya 
Dhatuposhan Abhava 
Vikrit Dhatu Utpatti  
Dhatukshaya 
Ojakshaya 
Rajyakshma 
Pratiloma 
Dhatukshaya 
Vata Dushti 
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Clinical Management of Rajyakshma in  
Ayurveda Literature17,18,19
It is advised to avoid purgation in Yakshma 
patients i.e. “Purisham Sanrakshyam”. Goat Milk, meat 
and soup of Jangal category animals, Yusha of grams 
& Green grams, Wheat, Seedhu, Arishta, Sura, Asava 
are advised as a Pathya (advocacy) in Yakshma. 
Rakayakshma disease is caused by Tridosha, so 
Vaidya should consider the state of Dosha and treat 
Tuberculosis according to the severity of the 
symptoms and patient’s condition. Most of the Yogas 
(formulations) mentioned in Jwara (Fever) treatment 
can be used along with Ghrita in the Yakshma for the 
symptoms like Jwara and Daha (burning sensation). 
Ghrita consumption after food is advised for 
Shirashoola (Headache), Parshvashoola, Ansashoola, 
Kasa and Shwasa. 
Panchakoladi Ghrita, Dashamooladya Ghrita, 
Kharjuradi Ghrita, Vasa Ghrita, Shatavari Ghrita, 
Duralabhadya Ghrita, Jeevantyadi Ghrita, Sitopaladi 
Churna, Talishadi Churna, are advised by Acharya 
Charaka for the treatment of Yakshma17. 
Brihan Chikitsa, Snigdha food and drink and 
Vatanashak medicines, food and drink are beneficial. 
Ashwagandhadi Churna, Ashwagandha Ksheera, 
Ashwagandha Utsadan, Vasaghrita, Eladi Ghrita, 
Rasona Yogas are advised by Acharya Sushruta.  
Dashamoola Ghrita, Jeevantyadi Ghria, 
Kharjura Shatpal Ghrita, Ashwagandha siddha milk 
and ghee extracted from that milk, Guda-Sarpi yoga 
are advised in Ashtang Hridya.  
The overall approach of the treatment is 
Deepan-Pachan, Laghu Santarpan and Brihan of 
weakened Dhatu (body tissues) and to boost the 
immunity of the patient by use of Rasayana 
(Immunomodulator) drugs.  
Ayurveda Products/Herbs for Tuberculosis 
Disorder
Chart 5: Showing Formulations mentioned in AFI which can be useful in Rajyakshma (TB) / Yakshma 
(TB) / Kshaya (Pthisis)21 
Dosage Form AFI Name of the Formulations 
Churna 
/Kwatha 
Churna 
AFI Part I 
Vidaryadi Kwatha Churna, Karpuradi Churna, Yavandyadi Churna, Drakshadi 
Churna, Narsimha Churna, Bhaskarlavan Churna, Sitopaladi Churna 
AFI Part II 
Agnimukha Churna, Ashwagandhadi Churna, Mahatalisadi Churna, 
Madhyamanayika Churna, Badaradya Churna, 
AFI Part III Lavangadi Curna, Yogaraja Rasayana 
Vati /Tablet 
/Guggulu 
AFI Part I 
Mahayogaraj Guggulu, Saptavimshatik Guggulu, Dhanvantar Gutika, Shiva 
Gutika, Shankhavati, Suvarna Vatak 
AFI Part II *Sanshamani Vati 
Asava 
/Arishta 
AFI Part I 
Kanakasava Kumaryasava-A, Kumaryasava-B, Dantadyarishta, 
Dashmoolarishta, Draksharishta, Pippalyadyasava, Vasakarishta 
AFI Part II Babbularishta 
Avleha /Paka 
/Khanda 
AFI Part I 
Agastyaharitaki Rasayana, Kushmandaka Rasayana, Guduchyadi Modaka, 
ChitrakHaritaki, *Chyavanprasha, Narikela Khanda, Guduchyadi Modaka, 
Pugakhsnda, *Vasavleha, Shatavari Guda 
AFI Part II Ardrakakhanda Avleha, Vyaghri Haritaki 
AFI Part III Methi Modaka, Abhayadi Modaka, Brihat Vasavaleha, 
Sneha /Taila 
/Ghrita 
AFI Part I 
Indukanata Ghrita, Eladi Ghrita, Chagaladya Ghrita, Nirgundi Ghrita, 
Panchatiktaguggulu Ghrita, Pippalyadi Ghrita, Vidaryadi Ghrita, Chandanadi 
Taila, Chandanbalalakshadi Taila, Bala Taila, Balashwagandhalakshadi Taila, 
Vasachandanadi Taila 
AFI Part II Madhyam Narayan Taila, Visnu Taila, Brihat Ashwagandha Ghrita 
 AFI Part I Guduchi Sattva  
Parpati 
/Rasayoga 
/Bhasma 
AFI Part I 
Kantavallabha Rasa, Rasasindura, Panchamrita Parpati, Svarna Parpati, 
Manikya Pishti, Kapardika Bhasma, Tamra Bhasma, Pravala Bhasma, Mukta 
Bhasma, YashadaBhasma, Vanga Bhasma, Vajra Bhasma, Vaikranta Bhasma, 
Svarna Bhasma, Svarnamakshika Bhasma, Haratala Bhasma, Chaturbhuja 
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Rasa, Chaturmukha Rasa, Navaratnarajmriganka Rasa, Nagavallabha Rasa, 
*Mahalaxmivilas Rasa, Muktapanchamrita Rasa, Yogendra Rasa, Rajmriganka 
Rasa, Laghumalinivasant Rasa, Laxmivilas Rasa, Vasantkusumakar Rasa, 
Svarnabhupati Rasa, Sutshekhar Rasa 
AFI Part II 
Akika Pishti, Akika Bhasma, Varatika Bhasma, Kanchanabhra Rasa, 
Kantavallabha Rasa, Grahanikapat Rasa, Vasantatilaka Rasa, Hemanath Rasa, 
Kanchanabhra Rasa, Brihachhanagarabhra Rasa, Shringabhra Rasa, 
Sutshekhar Rasa, Yogaraj, Shilajatvadi Lauha 
AFI Part III 
Vidyadharabhra Rasa, Kancanabhra Rasa, Brhat Sarvalokasraya Rasa, 
Mahasvasari Lauha, Svasakalesvara Rasa Sutasekhara Rasa 
(Svaranarupyarahita) 
Antitubercular Potential of some traditional herbs/Products 
MR Hema et al. in the bio-activity study of the 
methanol extract of Artocarpus integrifolia exhibited 
anti-tuberculosis activity, even at very low 
concentration (less than 1mg) which led to the 
isolation of two known compounds homopterocarpin 
and cycloheterophyllin22. 
Mahesh AR et al. found that water soluble portion 
of the methanolic extract of the dried peels of Citrus 
sinensis shows better antitubercular activity at 
50μg/ml23. 
Shivakumar BS et al. in his study observed that 
ethanol extract of the stem and leaves of Barlaria 
Buxifolia Linn Using Microplate Almar Blue Assay 
(MABA) was found to be active at minimum 
inhibitory concentrations (MIC) of 25 and 50μg/ml 
and provides potential for the development of 
urgently needed novel antituberculous 
therapeutics24. 
Ehsanifar et al. in his study, by using proportional 
method on 7 clinical samples and one reference 
sample with its six concentrations in addition to the 
effects of plant extracts in combination with 
rifampicin the Methanolic extract of Capparis spinosa 
plant revealed anti-mycobacterial effect25.  
Rahna K. Rathnan et al. in his study screened the 
antituberculosis properties of leaf and callus extracts 
of Ipomea turpethum by broth dilution method. 
Among the extract tested, they observed significant 
inhibitory activity in ethanol extract of leaf callus and 
the aqueous extract did not show any significant 
activity26. 
Villaflores, et al. studied on Alpinia purpurata or 
red ginger for its phytochemical constituents on 
Philippine Zingiberaceae plants that may exhibit 
antimycobacterial activity. This study demonstrates 
the promise of this plant as a source of 
phytomedicinals that can fight TB27.  
Kumar JK et al. conducted study on crude extracts 
of legume leaves of five medicinal plant i.e 
Kingiodendron pinnatum, Humboldtia brunonis, Derris 
scandens, Ceasalpinia mimosoides and Indigoferra 
cassiodes. In the result they showed that leaf extracts 
of these medicinal legumes possess anti-tubercular 
activity and offers the scope for the development of 
potential anti-tubercular crude drugs28. 
Sharma VK found in his study that aqueous 
extract of Henna has strong in vitro and in vivo 
tuberculostatic acitivity29. Subsequently Bina 
Shaheen Siddiqui et al. investigated the 
antituberculosis activity of six constituents including 
three triterpenoids, lawsowaseem, lawsonic acid, 
lawsonin; a dihydrobenzofuran derivative, 
lawsonicin; a naphthoquinone derivative, 
lawsonadeem, and vomifoliol isolated from the aerial 
parts of Lawsonia alba and validate the earlier 
findings of Sharma VK30.  
Archana Mehta, et al. showed that three isolated 
compounds from fruit of Citrullus colocynthis (ursolic 
acid, cucurbitacin, E 2-0-β-D-glucopyranoside and 
cucurbitacin E 2-0-β-Dglucopyranoside) having good 
anti-tubercular activity by inhibiting 7 non-MDR, 8 
MDR and 1 XDR M. tuberculosis and 2 MOTT clinical 
isolates. The bioactive fractions as a whole showed 
better antitubercular activity than the isolated 
compounds against the drug resistant and MOTT 
clinical isolates may be due to synergistic effect of 
other compounds31.  
B.S. Siddiqui et al. stated in his study that 
inhibition of M. tuberculosis by pure compounds 
from Ocimumbasilicum supports the use of this plant 
in ethno medicine as a remedy for symptoms of 
tuberculosis. They also suggested that the activity of 
the plant may be due to a synergistic effect of active 
compounds including those investigated in the 
present studies, and hence this plant is a potential 
candidate for obtaining further new antituberculosis 
natural products32.  
Shashikant Vaidya et al. in their study showed 
that aqueous & methanolic extracts of Cinnamomum 
prepared by soxhet extraction and their 
phytochemical analysis showed flavanoids, tannins, 
steroids & essential oils in both extracts. Study 
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demonstrated antituberculosis activity of plants, 
though antagonistic activity with INH33.  
Dini et al; in their review article mentioned 
studies carried out about antitubercular properties of 
Allium sativum both in vitro and in vivo is provided. 
The researches about the garlic extracts effectiveness 
against clinical isolates of MDR-TB are of scientific 
importance. Allium sativum offers a hope for 
developing alternative drugs. The involvement of 
traditional healers (TH) in the TB health 
management could facilitate the administration of 
garlic extracts to the infected patients34.  
Alka Sharma and Ashwani Kumar in their review 
article given various references for antitubercular 
activity of Justicaadhatoda plant35. 
Hepatoprotective activity of some traditional 
herbs/Products againstantitubercular drugs 
Geetha KM et al. found that aqueous alcoholic 
(70%) extract of Rhodomyrtus tomentosa exhibit 
hepatoprotective activity against antitubercular drug 
induced hepatotoxicity through a free radical 
scavenging effect and reduces oxidative damage 
caused by antitubercular drugs36. 
Chandane RD et al. in his study reveals that honey 
significantly prevent as well as reverse hepatotoxicity 
induced by antitubercular drugs in rats. Study 
concluded that honey by way of inhibiting lipid 
peroxidation and by increasing antioxidant defence 
mechanism has a significant hepatoprotective 
action37. 
B.P. KALE et al. stated that aqueous leaf extract 
Azadirachta indica significantly prevents and 
reverses the hepatotoxic damage induced by 
antitubercular drugs in rats38. 
Shoba Rani et al. found that methanolic pericarp 
extract of Sapindusemarginatus possess 
hepatoprotective activity against anti tubercular 
drugs induced liver damage in rats39.  
T.S.Panchabhai et al. seen the Hepatoprotective 
effect of two Indian medicinal plants Tinospora 
cordifolia (Tc), Phyllanthus emblica (Pe), and their 
combination, in a rat model of isoniazid, rifampicin 
and pyrazinamide induced hepatic damage40. 
S.A.Tasduq et al. showed that, 50% 
Hydroalcoholic Fruit Extract of Emblica officinalis 
have the hepatoprotective property against 
antituberculosis (anti-TB) drugs-induced hepatic 
injury in rats41. 
Current Practices & Researches in Tuberculosis: 
Ayurvedic treatment of tuberculosis was 
initiated in 1933, by the establishment of Patipukur 
Tuberculosis Hospital, Kolkata. Later, a full-fledged 
research unit was commissioned with exclusive 
budget. Treatment guidelines were adopted on 
Ayurvedic principles for therapeutic management 
which was a unique effort of its kind in Pre-
Independence India. This regimen was discontinued 
from 1st November 1947 on the introduction of 
synthetic ATDs. Drugs containing mercury, gold, 
calcium was prepared at the in-house pharmacy and 
was administered to the patients with fresh juice of 
herbs cultivated in the hospital garden. Formulations 
like Vasantamalati, Kanchanabhra rasa, 
Rajamrigankarasa were under use including 
Bhallataka (Semicarpusanacardium) Rasayan, 
Mallasindura, Vasa (Adatodavasica) etc. The statistics 
on the treatment of Tuberculosis using Ayurvedic 
medicine over a period of 13 years is of immense 
value42. 
The Renowned practitioner from 
Maharashtra Vaidya P T Joshi in his Post graduation 
thesis compilation ‘Role of Panchakarma in Acute 
stages of Disease’ mentioned a case study of 42 year 
male patient diagnosed as pulmonary Tuberculosis 
having symptoms of Haemopthasis, loss of weight & 
appetite, low grade fever and coughing for 3 years 
and treated by Shodhana (Vasa Ghrita-Swedana-
Vamana), and then Shamana (Draksharishta, Shringa 
Bhasma, Pipplai Rasayan) 
Ayurvedic treatment of Tuberculosis was 
common practice right until 1947, when modern 
anti-Tuberculosis drugs became available. Antibiotic 
Tuberculosis medications are very effective but 
eventually they are rendered ineffectual when drug 
resistant strains emerge. However, recent research 
proves that Ayurvedic treatments may hold the key 
to fighting this growing problem43. 
Chart 6: Showing details of Clinical Evidences conducted on Ayurveda Formulations. 
Study Type & Intervention Treatment Outcome Ref. 
Subhash Singh et al; Case Report 
36 year old female known case of drug resistant pulmonary 
TB  
Purification of body (Samsodhan): Snehapan uncted with 
Ghrit of goat and sheep processed with decoction of Laghu 
Panchmool for three days. On fourth day in the morning Piper 
longum (Pippali) powder 2g for mild emesis and Terminalia 
chebula (Haritaki) powder 6g for laxation  
Mahalaxmi Vilas Rasa is found useful 
for the treatment of TB. Drug is as 
effective as R H E & Z, available in 
conventional medicine for treatment 
of TB.  
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Oral treatment: After Samshodhana regular therapy with 
Mahalaxmi Vilas Ras 250 mg per day empty stomach in the 
morning  
Duration: for five years 
Deshpande Vaishali et. al.Case Study 
Female patient of 58 year along with ATT given 
Oral treatment: Kaishora Guggulu 500mg TDS AF with 
warm water, Samshamani Vati 1gm TDS AF with warm 
water. Combination (Swarna Malini Vasanta 60mg + Abhrak 
Bhasma 120mg + Chausasti Pippali 250 mg) BD with honey 
Panchakarma treatment: Gentle application of sesame oil 
on both lower extremities and Matra Basti of Guduchi Siddha 
Yamaka Sneha. 
Duration: 85 days 
After completing 55 Basti and 85 
days of oral treatment complete 
remission seen in low back pain, 
tingling, numbness, body ache, loss 
of appetite. Improvement in Muscle 
power and weight gain.  
45 
Singhal Pragya, Case Study 
50 year old male patient with past history of pulmonary TB 
Oral treatment: 
Vasa avhleha,1 tsf BD 
Talishadichoorna 3gm BD 
Godantibhasma 500mg BD 
Madhuyasthichoorna 3gm BD with milk 
Duration: 08 months 
Improvement in declining sputum 
production and cough relief, blood 
tinged sputum. Having no episode of 
chest infection during treatment and 
chest X-ray found normal after 
treatment.  
46 
Dr. A. P. Rana et al; Case Study 
 14 years old female patient known case of MDR TB 
Oral treatment:Jaimangal Rasa, Rajmrugank Rasa, 
Swarnasutshekhar Rasa, Shwas Kas Chintamani Rasa, Shwas 
Kuthar Rasa, Nagarjunabhra Rasa 
Panchakarma treatment:  
Bahya Abhyanga: KsheerBalaTaila 
Uro Abhyanga: BrihatShatavariTaila 
Significant relief in symptoms as 
compared to earlier severity. 
Improvement in appetite, weight 
gain, and help the patient to get back 
to his routine life after one year of 
regular treatment.  
47 
Sathya N. Dornalaet al; Clinical Trial 
Group of 60 patients of PTB divided into two equal groups. 
Control group: DOTS therapy 
Test group: DOTS for 6 or 8 months + Bhringarajasava (30 
ml thrice a day AF) for 2 or 3 months i.e., during the intensive 
phase. 
Follow‑up: 6‑8 months based on treatment category. 
The purpose is to improve the 
resistance of the patient to damage 
caused by the tubercle bacilli, and to 
create an environment in the body 
unsuitable for proliferation of the 
bacilli. Improvement in weight gain 
was also observed. 
 
48 
Purvi Vyas et al; Single Blind Controlled Trial 
133 patients of TB (Category-I) randomly divided into two 
groups 
Control group:Standard regime of RNTCP 
Study group: Rasayana compound (aqueous extract of 
Amalaki +Ashwagandha +Guduchi +Yashtimadhu +Sariva + 
Haridra +Pippali +Kushtha +Kulinjana) daily Three capsules 
morning and two capsules evening with milk along with the 
standard regimen of AKT 
Duration: 02 months 
Improvement in symptoms of Kasa 
(cough), Raktanisthivana, Shwasa, 
Parshwashoola, appetite, fatigue, 
Ratriprasweda, Body weight. Adjunct 
therapy of Rasayana drugs with AKT 
provides better physical and mental 
wellbeing to patient and also 
counteracting the unwanted effects 
caused by AKT. 
49 
Ranjeet Kumar et al; Randomized, Double-Blind Placebo-
Control Study 
Withaniasomnifera has shown better 
relief of symptoms andsignificantly 
50 
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60 newly diagnosed sputum smear positive cases of 
pulmonary TB on Directly Observed Treatment – short 
course (DOTS) regime divided in two groups. 
Study group: W.somnifera root extract capsule 500mg BD 
with water with DOTS 
Control group: placebo capsules containing dextrose 
powder along with DOTS 
Duration: 12 weeks 
favourable effects on liver 
transaminase levels and serum uric 
acid levels. It has also improved 
Health Related Quality of Life 
(HRQoL) scores in pulmonary TB 
patients. 
Sanjay Chhajed et al; Clinical Study 
23 patients of tuberculosis were randomly divided into three 
groups 
Standard Group (7 patients): DOTS regime 
Ashvagandha Group (8 patients): Ashvagandgā Kshirapaka 
in the dose of 300 mg/kg/day with DOTS 
Pippali Group (8 patients): Pippali Kshirapaka in the dose of 
150 mg/kg/day with DOTS 
Addition of Pippali and Ashvagandha 
as adjuvant to the modern anti 
Koch’s treatment (AKT) helps in 
providing better and faster relief as 
well as in preventing their side 
effects. The effect of Pippali seems to 
better in respect to Ashvagandha.  
51 
Debnath et al; Pilot study and an 
open labelled trial with therapeutic control add on 
therapy  
99 newly diagnosed pulmonary tuberculosis patients 
randomly divided into different groups 
Aswagandha (Withania somnifera) capsule 500mg - 2 caps 
twice daily for 28 days 
Chyawanprash - 10 g thrice daily for 28 days 
The symptoms subsided, body 
weight showed improvement, ESR 
values were normal, there was an 
appreciable change in IgA and IgM 
patterns and significantly increased 
the bioavailability of isoniazid and 
pyrazinamide were recorded. 
42 
Sharma et al; Clinical Trial 
Known cases of TB put on the antitubercular treatment were 
taken in study. 40 patients registered out of 10 patients in 
each group completed trial  
Group A: Liv-600 Capsule (200mg each Hydroalcoholic 
extract of Daruharidra, Kakamachi, Ghritkumari) TDS 
Group B: Decoction of 10gm of Bhumyamalaki (Phyllanthus 
fraternus) OD 
Group C: Placebo 600mg Capsule 
Duration: 90 days 
Both of these preparationsexhibited 
hepato- protective properties 
compared to the placebo treatment 
on periodic liverfunctions 
evaluations 
52 
Narayana, D.B.A., et al; Randomized controlled 
Trial 
90 patients of pulmonary tuberculosis taking ATD are 
divided in three groups  
Group I: 10 g of Chyavanprash (CP) twice a day as an 
adjuvant therapy, in addition to ATD 
Group II (Combine therapy): Combination of anabolic 
steroid (25mg once a week IM), protein supplement (2 tea 
spoonful or 4g thrice a day) and vitamins (one cap/day) 
along with ATD 
Group-III: only ATDs without an adjuvant 
Therapy 
Symptoms like Cough, expectoration, 
weakness, loss of appetite, loss of 
weight, fever, oedema aches and 
haemoptysis almost disappeared in 
CP and combine therapy group 
completely as compare to group III. 
Mean of weight gain and serum 
protein was better in CP group 
compared to other group.  
Improvement in the Hb levels was 
seen in CP and combine therapy 
group.  
Comparison of X-ray chest before 
and after treatment showed 
Effective healing in CP and combine 
therapy group compared to the 
observations in group-III. 
53 
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Kurane SB et al; Randomized control trial Group 
Sixty patients who had completed treatment for pulmonary 
tuberculosis were divided into two groups of thirty each. 
Group A: Kharjuradi Ghrita 20ml Rasayankale 
Group B: Kharjuradi Ghrita 20ml Rasayankale and 
Pranayama exercise daily once. 
Duration: 3months 
 
The Kharjuradighrita gives 
significant results in the period of 
post tuberculous treatment to 
increase appetite, to strengthen body 
and to tackle different diseases like 
Kasa, Jwara etc. 
Pranayam is a body and mind 
strengthening exercise and helps to 
recover the damage that took place 
due to pulmonary tuberculosis 
54 
Kale NB,Case Study 
30 year old female patienttreated with Anti- Tubercular 
drugs i.e. DOTS (Directly observed treatment 
shortchemotherapy) of category – I along with Jivantyadi 
Ghrita 10ml BD with milk for six months. 
Jivantyadi Ghrit of Rajyakshma 
Rogadhikar along with DOTS (CAT–I) 
helpful in improving the appetite, 
reduces the local inflammation & 
improve the function of genital organ 
which initiates the regular & 
adequate menses. It also reduces the 
side effects of anti – tubercular drugs 
and ultimately responsible for 
improvement in general metabolism 
& condition of the patient. 
55 
DISCUSSION: 
Tuberculosis being the world’s deadliest 
infectious killer despite the availability of highly 
efficacious treatment, it is a serious health threat, 
especially for people living with HIV. People living 
with HIV are more likely than others to become sick 
with TB. Worldwide, TB is one of the leading causes 
of death among people living with HIV. Without 
treatment, as with other opportunistic infections, HIV 
and TB can work together to shorten life span. Drug-
induced hepatotoxicity (DIH) is the most common 
adverse drug reaction leading to interruption of 
antituberculosis treatment. Worldwide, different 
reintroduction regimens have been advocated, but no 
consensus guidelines are available. Reintroduction of 
antitubercular drugs in patients with DIH has never 
been studied systematically. 
Ayurveda is living science which helpful to 
everyone to be a healthy by advocacy of lifestyle and 
treatment by universal principle. As per Ayurveda, 
classification of Tuberculosis as a Trirupa, Shadrupa, 
Ekadashrupa may be for the assessment of the 
severity and prognosis of the disease. It is time to 
conduct more systematic research on this aspect 
Trirupa, Shadrupa, Ekadashrupa Rajyakshma which 
can be beneficial in the management of TB to 
improve quality of life.  
As mentioned, HIV and Tuberculosis are work 
together to shorten lifespan and, risk of TB infection 
and mortality is much higher in patients infected 
with HIV; in both conditions, Ayurveda considered 
Dhatvagnimandya and Oja Dushti as a main 
pathological events or clinical feature in Tuberculosis 
and Dhatvagnivardhak (metabolism enhancer) and 
Ojovardhak Rasayana (immune modulators) 
treatment can be helpful to improve their lifespan.  
In present scenario the role of Ayurveda in 
the management of TB is very scanty and mostly 
limited to adjunct or supportive therapy which 
cannot be simply neglected. The supportive or 
adjunct therapy of Ayurveda intervention can be 
helpful to improve quality of life of the patient, to 
avoid hepatotoxic effect of the drug, to increase the 
bioavailability of the drug as well as to reduce the 
treatment duration.  
Most of the physicians are currently using 
Ayurveda preparations having Tikta (Bitter) Rasa 
dominant ingredients and used in Ghrita and 
Kshirapaka dosage as an adjunct to tuberculosis 
treatment. Some of the clinical evidences are also 
generated for herbs like Ashwagandha, Pippali, Garlic, 
Guduchi, Amalaki and preparations like Vasa Ghita, 
Jeevantyadi Ghrita, Kharjuradi Ghrita, Chyavanprash, 
Bhringarajasava, Mahalaxmivilas Rasa which are 
proven beneficial in the management of tuberculosis.  
The accountability and reproducibility of the 
evidences presented in this review are again a 
debatable issue. More scientific evidences of 
Ayurvedic principle and their treatment modalities 
on tuberculosis are need to be published in highly 
reputed journal in future, and for that purpose 
collaborative approach is needed from modern as 
well as Ayurveda fraternity.  
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CONCLUSION 
Need of collaborative approach from modern 
as well as traditional system of medicine, to conduct 
a more research on Ayurveda formulations and single 
herbs having Rasayana properties; which will 
generate the evidence base medicine. While 
conducting a research on Ayurveda preparations it is 
essential to find out any kind of drug interactions 
with standard antitubercular drugs to establish the 
safety of adjunct medicine. Scientific Collaborative 
approach will be benefited to the society to improve 
the quality of life of the patient, to reduce the 
hepatotoxicity, incidence of MDR Tuberculosis and to 
extend the life span of the patients. 
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